Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
Volume 0.07M
Average 0.62M
EDSA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Edesa Biotech, Inc.NASDAQ: EDSA
EBITDA · Q2 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$4.27M, compared with -$1.56M a year earlier. Trailing-twelve-month EBITDA was -$10.48M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Sep 2026, a step up from the -18.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.27M-84.4% QoQ
- Last fiscal yearSep 2025
- -$7.07M-18.1% YoY
- LTMMar 2026
- -$10.48M-85.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -173.4% | +100.0% | +273.4 pp |
| 1 year | -18.1% | +100.0% | +118.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (7.07M) USD
- Year-over-year change
- -18.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (7.07M) | -18.1% |
| FY2024 | 2024-09-30 | (5.98M) | +26.9% |
| FY2023 | 2023-09-30 | (8.19M) | +53.0% |
| FY2022 | 2022-09-30 | (17.43M) | -31.8% |
| FY2021 | 2021-09-30 | (13.22M) | — |
EBITDA vs competitors
How EDSA compares with its peers on the latest reported figures
- EDSA's LTM Mar 2026 EBITDA of -$10.48M is the highest of the 2 companies compared; the peer median is -$28.24M.
- Its year-over-year change of -85.4% is the lowest of 2, against a peer median of -31.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$10.48M | -85.4% | — | — | |
| LTM Mar 2026 | -$28.24M | -31.5% | — | — | |
| Peer median (excluding EDSA) | -$28.24M | -31.5% | — | — | |
Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| Gross Profit | (118.79K) | (118.19K) | (183.47K) | (186.05K) | (119.27K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 17.95M | 13.34M | 4.79M | 2.88M | 3.67M |
| Selling, General & Admin | 5.73M | 5.04M | 4.43M | 4.13M | 4.24M |
| Operating Expenses | 23.68M | 18.37M | 9.22M | 7.01M | 7.79M |
| Depreciation & Amortization | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| EBITDA | (13.22M) | (17.43M) | (8.19M) | (5.98M) | (7.07M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (23.68M) | (18.37M) | (9.22M) | (7.01M) | (7.91M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 11.17K | 64 | 289.85K | 153.5K | 2.56K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 10.34M | 822.67K | 849.14K | 845.5K | 726.84K |
| Income Before Tax | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.18M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 800 | 800 | 800 | 800 | 800 |
| Net Income | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.74) | (8.37) | (2.93) | (1.93) | (1.27) |
| EPS (Diluted) | (7.73) | (8.37) | (2.93) | (1.93) | (1.27) |
| Weighted Avg Shares | 1.73M | 2.1M | 2.86M | 3.2M | 5.68M |
| Weighted Avg Shares (Diluted) | 1.73M | 2.1M | 2.86M | 3.2M | 5.68M |
Edesa Biotech, Inc.
NASDAQ:EDSA
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.